Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 12:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 13,606 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatologic Disorders Clear all
Completed Phase 1 Interventional

A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer

NCT00732056
View directory record Official record
Conditions
Breast Cancer
Interventions
GRN163L
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Harvey, Illinois • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 28, 2026, 12:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Macrobiotic Diet and Flax Seed: Effects on Estrogens, Phytoestrogens, & Fibrinolytic Factors

NCT00010829
View directory record Official record
Conditions
Cardiovascular Diseases, Osteoporosis, Breast Cancer, Endometrial Cancer
Interventions
American Heart Association Step 1 diet, American Heart Association Step 2 diet + 10 g/day flax seed, Macrobiotic dietary intervention
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
50 Years to 72 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 28, 2026, 12:22 AM EDT
Completed Phase 2 Interventional Results available

A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease

NCT03582137
View directory record Official record
Conditions
Parkinson Disease
Interventions
Cannabidiol, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 28, 2026, 12:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Plant-based Dietary Intervention for Treatment of Acne

NCT00900939
View directory record Official record
Conditions
Acne
Interventions
Low-fat, vegan diet, Control
Behavioral
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 28, 2026, 12:22 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer

NCT00077857
View directory record Official record
Conditions
Breast Cancer
Interventions
capecitabine (Xeloda®), docetaxel (Taxotere®)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
43
States / cities
Birmingham, Alabama • Hoover, Alabama • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated May 10, 2013 · Synced Oct 28, 2026, 12:22 AM EDT
Completed Phase 2 Interventional Results available

Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma

NCT01927419
View directory record Official record
Conditions
Unresectable Melanoma, Metastatic Melanoma
Interventions
Nivolumab, Ipilimumab, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
19
States / cities
San Francisco, California • Orlando, Florida • Louisville, Kentucky + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 28, 2026, 12:22 AM EDT
Completed Phase 1 Interventional

Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors

NCT02391727
View directory record Official record
Conditions
Colon Cancer, Breast Cancer, Cancer of the Head and Neck
Interventions
SYN004
Biological
Lead sponsor
Synermore Biologics Co., Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
New Orleans, Louisiana • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 28, 2026, 12:22 AM EDT
Completed Phase 3 Interventional Results available

A Study of Golimumab in Participants With Active Psoriatic Arthritis

NCT02181673
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Placebo, Golimumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
13
States / cities
Glendale, Arizona • Mesa, Arizona • Huntington Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Oct 28, 2026, 12:22 AM EDT
Completed Phase 4 Interventional

Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis

NCT00460083
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Elidel(R) (pimecrolimus 1%), EpiCeram(R) -ceramide based barrier repair cream
Drug · Device
Lead sponsor
Ceragenix Pharmaceuticals
Industry
Eligibility
2 Years to 12 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
San Diego, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 6, 2008 · Synced Oct 28, 2026, 12:22 AM EDT
Completed No phase listed Observational

A Study of Real-world Outcomes Among Patients Treated With Ribociclib

NCT07148505
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 28, 2026, 12:22 AM EDT
Completed Not applicable Interventional

Making it Work Program for Systemic Sclerosis

NCT06338722
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Making it Work Systemic Sclerosis
Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 67 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 28, 2026, 12:22 AM EDT
Completed No phase listed Observational

Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer

NCT05071677
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Discussion, Interview, Survey Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 28, 2026, 12:22 AM EDT
Completed Phase 2 Interventional Results available

Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate

NCT03221257
View directory record Official record
Conditions
Scleroderma, Systemic, Interstitial Lung Disease
Interventions
Pirfenidone (PFD), Placebo (Plac), Mycophenolate Mofetil (MMF)
Drug
Lead sponsor
Michael Roth
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
16
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 28, 2026, 12:22 AM EDT
Completed No phase listed Observational

Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis

NCT01556503
View directory record Official record
Conditions
Melanoma
Interventions
VivaScope System
Device
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
12 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 25, 2016 · Synced Oct 28, 2026, 12:22 AM EDT
Completed Phase 2 Interventional Results available

Self Hypnotic Relaxation As An Adjunct To Local Anesthesia During Large Core Breast Biopsy

NCT00122369
View directory record Official record
Conditions
Breast Cancer, Anxiety, Pain
Interventions
Self-hypnotic Relaxation, Empathic Attention
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 28, 2026, 12:22 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris

NCT01974141
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone Gel, Dapsone Gel Vehicle
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
12 Years and older
Enrollment
2,102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Encino, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 28, 2026, 12:22 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis

NCT02479139
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Vehicle, ANT-1207
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 70 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
19
States / cities
Hialeah, Florida • Miami, Florida • Pinellas Park, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 28, 2026, 12:22 AM EDT
Completed No phase listed Observational

Skin Tracker: A Mobile Health App to Monitor Skin Disease Activity and Treatment Use

NCT04404075
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
SkinTracker Mobile App
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
11 participants
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 28, 2026, 12:22 AM EDT
Enrolling by invitation Phase 4 Interventional

Evaluating Whether Intact Fish Skin Graft Can Decrease the Need for Autograft in the Treatment of Deep Partial-Thickness Burns

NCT07326657
View directory record Official record
Conditions
Partial-thickness Burn Wounds
Interventions
Intact fish skin graft, autograft
Device · Procedure
Lead sponsor
Kerecis Ltd.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 28, 2026, 12:22 AM EDT
Completed Not applicable Interventional Results available

An RCT on Support Surfaces for Pressure Ulcer Prevention

NCT03351049
View directory record Official record
Conditions
Pressure Injury, Pressure Ulcer
Interventions
LAL, Non-LAL
Device
Lead sponsor
David Brienza
Other
Eligibility
18 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 28, 2026, 12:22 AM EDT
Active, not recruiting Not applicable Interventional

4:3 Intermittent Fasting Intervention in Adults With Breast Cancer and Overweight or Obesity

NCT06399276
View directory record Official record
Conditions
Breast Cancer
Interventions
Weight Loss
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 28, 2026, 12:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Phenotypic and Genetic Properties in Males at Risk for X-linked Hypohidrotic Ectodermal Dysplasia: Evaluation of an Early Diagnosis Technology and Tests to Assess Nutritional Status

NCT01629940
View directory record Official record
Conditions
X-linked Hypohidrotic Ectodermal Dysplasia, Hypohidrotic Ectodermal Dysplasia
Interventions
Not listed
Lead sponsor
Edimer Pharmaceuticals
Industry
Eligibility
Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 28, 2026, 12:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PROSPR/PCIPS Project 3: Communication of Personalized Breast Cancer Risk

NCT01879189
View directory record Official record
Conditions
Breast Cancer
Interventions
Breast Cancer Screening Decision Aid
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
39 Years to 48 Years · Female only
Enrollment
1,302 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
9
States / cities
Philadelphia, Pennsylvania • Radnor, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 28, 2026, 12:22 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

NCT01693068
View directory record Official record
Conditions
N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
Interventions
Pimasertib, Dacarbazine
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 28, 2026, 12:22 AM EDT